Are there useful biomarkers for gastric cancer?
Authors:
- F. Di MarioFMF. Di Mario
- L.G. CavallaroLCL.G. Cavallaro
- G.M. CavestroGCG.M. Cavestro
- A. FranzéAFA. Franzé
- 1 May 2006
- journal article
- editorial
- Published by Elsevier in Digestive and Liver Disease
- Vol. 38 (5) , 308-309
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Anti-parietal cell antibody and serum pepsinogen assessment in screening for gastric carcinomaDigestive and Liver Disease, 2006
- Biomarkers in Patients with Gastric Inflammation: A Systematic ReviewDigestion, 2005
- Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacter pylori antibodies in the management of dyspeptic patients in primary careDigestive and Liver Disease, 2005
- Clinical Usefulness of Serum Pepsinogen II in the Management of Helicobacter pylori InfectionDigestion, 2004
- Recent Advances in Molecular Diagnosis and Therapy of Gastric CancerDigestive Diseases, 2004
- Atrophic Gastritis Serum Levels of Amidated Gastrin-17 and Pepsinogen I in Atrophic Gastritis: An Observational Case-Control StudyScandinavian Journal of Gastroenterology, 2002
- Helicobacter pyloriInfection and the Development of Gastric CancerNew England Journal of Medicine, 2001
- Interleukin-1 polymorphisms associated with increased risk of gastric cancerNature, 2000
- Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritisGastroenterology, 1996
- Serological tests to monitor treatment of Helicobacter pyloriThe Lancet, 1992